Evidence map›Paper›PMID 35024855›Full record

ArticleHuman molecular genetics2022

Pathogenic SLC25A26 variants impair SAH transport activity causing mitochondrial disease.

Florian A Rosenberger, Jia Xin Tang, Kate Sergeant, Marco F Moedas, Charlotte M Zierz, David Moore, Conrad Smith, David Lewis, Nishan Guha, Sila Hopton and 8 more

Open access · hybridAbstract read
In one paragraph

Article in Human molecular genetics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. From the cytosol to the inner membrane: biogenesis of the mitochondrial carrier family.Protein science : a publication of the Protein Society · 2026
    Review
  3. Review
  4. Article
  5. Article
  6. Fresh Insights IntoOncology reviews · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 7 institutions in 2 countries.

Florian A RosenbergerDepartment of Medical Biochemistry and Biophysics, Karolinska Institute, 171 65 Stockholm, Sweden.ORCID 0000-0003-4604-6170
Jia Xin TangFaculty of Medical Sciences, Wellcome Centre for Mitochondrial Research, Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne NE2 4HH, UK.
Kate SergeantOxford Regional Genetics Laboratories, Oxford University Hospitals NHS Foundation Trust, Oxford OX3 7LE, UK.
Marco F MoedasDepartment of Medical Biochemistry and Biophysics, Karolinska Institute, 171 65 Stockholm, Sweden.
Charlotte M ZierzFaculty of Medical Sciences, Wellcome Centre for Mitochondrial Research, Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne NE2 4HH, UK.
David MooreDepartment of Medical Biochemistry and Biophysics, Karolinska Institute, 171 65 Stockholm, Sweden.
Conrad SmithOxford Regional Genetics Laboratories, Oxford University Hospitals NHS Foundation Trust, Oxford OX3 7LE, UK.
David LewisDepartment of General Medicine, Oxford University Hospitals NHS Foundation Trust, Oxford OX3 9DU, UK.
Nishan GuhaDepartment of Clinical Biochemistry, Oxford University Hospitals NHS Foundation Trust, Oxford OX3 9DU, UK.
Sila HoptonFaculty of Medical Sciences, Wellcome Centre for Mitochondrial Research, Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne NE2 4HH, UK.
Gavin FalkousFaculty of Medical Sciences, Wellcome Centre for Mitochondrial Research, Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne NE2 4HH, UK.
Amanda LamNeurometabolic Unit, Institute of Neurology, Queen Square House, London WC1N 3BG, UK.
Angela PyleFaculty of Medical Sciences, Wellcome Centre for Mitochondrial Research, Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne NE2 4HH, UK.
Joanna PoultonNuffield Department of Women's and Reproductive Health, University of Oxford, Oxford OX3 9DU, UK.
Gráinne S GormanFaculty of Medical Sciences, Wellcome Centre for Mitochondrial Research, Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne NE2 4HH, UK.
Robert W TaylorFaculty of Medical Sciences, Wellcome Centre for Mitochondrial Research, Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne NE2 4HH, UK.
Christoph FreyerDepartment of Medical Biochemistry and Biophysics, Karolinska Institute, 171 65 Stockholm, Sweden.ORCID 0000-0003-0418-1673
Anna WredenbergDepartment of Medical Biochemistry and Biophysics, Karolinska Institute, 171 65 Stockholm, Sweden.
Newcastle upon Tyne Hospitals NHS Foundation Trust · GBOxford University Hospitals NHS Trust · GBKarolinska Institutet · SEWellcome Centre for Mitochondrial Research · GBKarolinska University Hospital · SENational Hospital for Neurology and Neurosurgery · GBUniversity of Oxford · GB

Funding

Resource Component: Acquisition, maintenance and distribution of Drosophila stocksP40OD018537 · OD · TRUSTEES OF INDIANA UNIVERSITY · PI Annette L. Parks · 2014 to 2026
$13.5M
NIH HHS P40 OD018537Wellcome Trust
6 · The paper itself

Abstract

The SLC25A26 gene encodes a mitochondrial inner membrane carrier that transports S-adenosylmethionine (SAM) into the mitochondrial matrix in exchange for S-adenosylhomocysteine (SAH). SAM is the predominant methyl-group donor for most cellular methylation processes, of which SAH is produced as a by-product. Pathogenic, biallelic SLC25A26 variants are a recognized cause of mitochondrial disease in children, with a severe neonatal onset caused by decreased SAM transport activity. Here, we describe two, unrelated adult cases, one of whom presented with recurrent episodes of severe abdominal pain and metabolic decompensation with lactic acidosis. Both patients had exercise intolerance and mitochondrial myopathy associated with biallelic variants in SLC25A26, which led to marked respiratory chain deficiencies and mitochondrial histopathological abnormalities in skeletal muscle that are comparable to those previously described in early-onset cases. We demonstrate using both mouse and fruit fly models that impairment of SAH, rather than SAM, transport across the mitochondrial membrane is likely the cause of this milder, late-onset phenotype. Our findings associate a novel pathomechanism with a known disease-causing protein and highlight the quests of precision medicine in optimizing diagnosis, therapeutic intervention and prognosis.

Indexed as

Mitochondrial DiseasesS-AdenosylhomocysteineAnimalsMethylationMiceMitochondriaS-AdenosylmethionineS-AdenosylhomocysteineS-Adenosylmethionine

Identifiers

PMID35024855
PMCPMC9239748
OpenAlexW4205460921

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.